SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., Aug. 17, 2020 /PRNewswire/ — United Therapeutics Corporation (Nasdaq: UTHR) today announced that the U.S. Food and Drug Administration (FDA) accepted for review the supplemental New Drug Application (sNDA) for Tyvaso® (treprostinil) Inhalation Solution for the treatment of pulmonary hypertension associated with interstitial lung disease (PH-ILD). United Therapeutics expects the agency’s review to be complete in April 2021.
It takes no time for Francis Collins, the director of the National Institutes of Health, to recall the moment when he knew he wanted to be a scientist. “Tenth-grade chemistry class,” he says over the phone from his home office in Chevy Chase, Md., where he has been working since most of the NIH campus in Bethesda, Md., shut down in March. Much of the science he had learned before then was “descriptive” and uninteresting, he explains—but for this class, students used experiments to figure things out. “It became clear to me that science is like a detective story,” says Dr. Collins, 70. “If you’re good at it, you’ll discover…
The 2020 Technology Showcase is going virtual! Reserve the afternoon of September 9th on your calendar for the 2020 Technology Showcase. The 4th annual event will highlight technologies being developed at the NCI and the Frederick National Laboratory for Cancer Research (FNL) to encourage technology licensing and collaborations, startup company formation and the translation of NCI discoveries into solutions to benefit patients.
This invitation-only event is free for executive level biotech leaders and is presented by BioHealth Innovation, Virginia Bio, Children’s National Health System, Johns Hopkins University, JPMorgan, Maryland Department of Commerce, George Mason University, University System of Maryland, Wilson Sonsini Goodrich & Rosati, AstraZeneca, Deloitte, and Montgomery County Economic Development Corp.
The BioHealth Capital Region—Maryland, Virginia, and Washington, DC—sets the bar high for biotech innovation. So please join us for our 6th Annual BioHealth Capital Region Forum that will highlight the accomplishments of today and chart our successes of tomorrow.
For more information about our speakers and event schedule, please visit www.biohealthcapital.com/forum-2020
#BHCRForum20
Are you a start-up in Maryland, DC or Virginia seeking feedback on your biohealth business idea, pitch deck, or commercialization plan? Schedule your complimentary virtual feedback session with BHI Entrepreneurs-in-Residence and Analysts on one of the following dates: 8/26. (45 minute blocks of time beginning at 9:00 in the morning. Pre-registration is required; sign up www.tinyurl.com/EIRFeedback. For questions/more information, contact BHI
Maryland has become a key part of the strategy for Kite, a Gilead company, and its mission to find a cure for cancer. As the California-based company focuses more and more on cutting-edge cell therapy research and manufacturing, Kite is expanding its toehold in the BioSpace Hotbed region known as BioCapital.
Baltimore, MD. (Aug. 10, 2020) — The University System of Maryland (USM) Momentum Fund has invested $250K in miRecule, an emerging biotech company with a cutting-edge discovery platform to create RNA therapeutics alongside theFSHD Society as a co-investor. This investment is complemented by recent funding raised over the past year, which includes lead investor Alexandria Venture Investments as well as Pathway Bioventures, Alumni Ventures Group, and angel investors. In total, miRecule’s seed round raised more than $3.5M in private seed funding. In addition to its private investments miRecule has also been awarded a non-dilutive $2M Phase II Small Business Innovation Research (SBIR) grant from the National Cancer Institute.
ROCKVILLE, Md., Aug. 12, 2020 /PRNewswire/ — Emmes today announced that it provided the data and statistical analysis support for the Phase 1 clinical trial of the investigational COVID-19 vaccine mRNA-1273. Three Emmes employees were co-authors on the Preliminary Report about the clinical trial, “An mRNA Vaccine against SARS-CoV-2,” published in the New England Journal of Medicine on July 14.
Emergent BioSolutions CEO Bob Kramer joined Jim Cramer on “Mad Money” to discuss the biopharmaceutical company’s role in the quest to bring a Covid-19 vaccine to market.
PASADENA, Calif., Aug. 13, 2020 /PRNewswire/ — Alexandria Real Estate Equities, Inc. (NYSE: ARE), an urban office REIT and the first, longest-tenured and pioneering owner, operator and developer uniquely focused on collaborative life science, technology and agtech campuses in AAA innovation cluster locations, is at the vanguard of the vital life science ecosystem that is advancing solutions for COVID-19 through a multifaceted, highly impactful strategy that includes a mission-critical focus on making rapid COVID-19 testing available to all Americans. Widespread screening and diagnostic testing, in addition to safe and effective vaccines and therapies, are desperately needed to resolve the global COVID-19 pandemic.
